Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination

Background Clinical trials that end prematurely (or “terminate”) raise financial, ethical, and scientific concerns. The extent to which the results of such trials are disseminated and the reasons for termination have not been well characterized. Methods and Findings A cross-sectional, descriptive study of terminated clinical trials posted on the ClinicalTrials.gov results database as of February 2013 was conducted. The main outcomes were to characterize the availability of primary outcome data on ClinicalTrials.gov and in the published literature and to identify the reasons for trial termination. Approximately 12% of trials with results posted on the ClinicalTrials.gov results database (905/7,646) were terminated. Most trials were terminated for reasons other than accumulated data from the trial (68%; 619/905), with an insufficient rate of accrual being the lead reason for termination among these trials (57%; 350/619). Of the remaining trials, 21% (193/905) were terminated based on data from the trial (findings of efficacy or toxicity) and 10% (93/905) did not specify a reason. Overall, data for a primary outcome measure were available on ClinicalTrials.gov and in the published literature for 72% (648/905) and 22% (198/905) of trials, respectively. Primary outcome data were reported on the ClinicalTrials.gov results database and in the published literature more frequently (91% and 46%, respectively) when the decision to terminate was based on data from the trial. Conclusions Trials terminate for a variety of reasons, not all of which reflect failures in the process or an inability to achieve the intended goals. Primary outcome data were reported most often when termination was based on data from the trial. Further research is needed to identify best practices for disseminating the experience and data resulting from terminated trials in order to help ensure maximal societal benefit from the investments of trial participants and others involved with the study.

[1]  G. Helgesson,et al.  Early Stopping of Clinical Trials: Charting the Ethical Terrain , 2011, Kennedy Institute of Ethics journal.

[2]  R. Califf,et al.  Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. , 2014, American heart journal.

[3]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[4]  Paolo Boffetta,et al.  Adult cancer clinical trials that fail to complete: an epidemic? , 2014, Journal of the National Cancer Institute.

[5]  Dina Demner-Fushman,et al.  Application of Information Technology: Essie: A Concept-based Search Engine for Structured Biomedical Text , 2007, J. Am. Medical Informatics Assoc..

[6]  Tony Tse,et al.  Update on Registration of Clinical Trials in ClinicalTrials.gov. , 2009, Chest.

[7]  Ida Sim,et al.  Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis , 2008, PLoS medicine.

[8]  W. McCaskill-Stevens,et al.  The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. , 2013, Journal of oncology practice.

[9]  S. Belknap,et al.  Characteristics and Causes for Non-Accrued Clinical Research (NACR) at an Academic Medical Institution , 2013, Journal of clinical medicine research.

[10]  Claire Snowdon,et al.  Does it matter if clinicians recruiting for a trial don't understand what the trial is really about? Qualitative study of surgeons' experiences of participation in a pragmatic multi-centre RCT , 2007, Trials.

[11]  Nicholas C. Ide,et al.  Issues in the registration of clinical trials. , 2007, JAMA.

[12]  Robert M Califf,et al.  Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. , 2012, JAMA.

[13]  Tony Tse,et al.  Reporting "basic results" in ClinicalTrials.gov. , 2009, Chest.

[14]  M. Lauer,et al.  Publication of trials funded by the National Heart, Lung, and Blood Institute. , 2014, The New England journal of medicine.

[15]  J. Ioannidis.  Clinical trials: what a waste , 2014, BMJ : British Medical Journal.

[16]  Isabelle Boutron,et al.  Timing and Completeness of Trial Results Posted at ClinicalTrials.gov and Published in Journals , 2013, PLoS medicine.

[17]  R. Gray,et al.  Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups , 2011, Clinical Cancer Research.

[18]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[19]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[20]  Tim Ramsay,et al.  Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials , 2015, Clinical trials.

[21]  Nicholas C. Ide,et al.  The ClinicalTrials.gov results database--update and key issues. , 2011, The New England journal of medicine.

[22]  Gordon H Guyatt,et al.  Randomized trials stopped early for benefit: a systematic review. , 2005, JAMA.

[23]  Ralph Lazzara,et al.  The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1994, Circulation.

[24]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2011, BMJ : British Medical Journal.

[25]  D. Altman,et al.  Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research , 2004, Canadian Medical Association Journal.

[26]  D. Dilts,et al.  The Prevalence and Economic Impact of Low-Enrolling Clinical Studies at an Academic Medical Center , 2011, Academic medicine : journal of the Association of American Medical Colleges.

[27]  B. Freidlin,et al.  Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Rennie,et al.  Stopping medical research to save money: a broken pact with researchers and patients. , 2003, JAMA.

[29]  Harlan M Krumholz,et al.  Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis , 2012, BMJ : British Medical Journal.

[30]  G. Guyatt,et al.  Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. , 2010, JAMA.

[31]  H. Krumholz,et al.  Reporting of results in ClinicalTrials.gov and high-impact journals. , 2014, JAMA.

[32]  E. Harrison,et al.  Discontinuation and non-publication of surgical randomised controlled trials: observational study , 2014, BMJ : British Medical Journal.

[33]  Ignacio Ferreira-González,et al.  Prevalence, characteristics, and publication of discontinued randomized trials. , 2014, JAMA.

[34]  F. J. Rodino.  Publication of trials funded by the National Heart, Lung, and Blood Institute. , 2014, The New England journal of medicine.

[35]  Jeanne-Marie Guise,et al.  Reporting Discrepancies Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications , 2014, Annals of Internal Medicine.

[36]  Lippincott Williams Wilkins,et al.  The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1994, European heart journal.

[37]  B. Freidlin,et al.  Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report , 2011, The American journal of bioethics : AJOB.